Jiangsu Yuyue Science & Technology Development

Wu Guangming, founder and chairman of Yuwell Medical, directly oversees the corporate investment function. The vehicle operates with founder-level authority and does not report to external limited partners. Wu's son, Wu Qun, runs the day-to-day operations of the underlying medical-device business as CEO.

It is a corporate balance-sheet investor. Unlike a venture capital firm structured with blind pools of external capital, Jiangsu Yuyue Science & Technology Development deploys directly from the listed parent company's treasury. This structure allows it to hold investments indefinitely and pursue both minority venture bets and full strategic acquisitions, such as the Esaote buyout.

The firm concentrates on medical devices, diagnostics, and consumer health. Its parent company, Yuwell Medical, produces home-use respiratory and monitoring devices, and the investment portfolio has historically extended into medical imaging — including the previous Wandong Medical stake and the Esaote acquisition in the MRI and ultrasound space (per Reuters, 2018).

Jiangsu Yuyue Science & Technology Development demonstrated cross-border appetite through the 2018 acquisition of Italy-based Esaote, a diagnostic-imaging company with a strong European install base. The deal was executed in partnership with Yunfeng Capital, Jack Ma's private-equity firm, signaling a willingness to co-invest with external partners for offshore deals.

No. The firm does not publicly disclose an AUM figure for its investment division. Since it deploys capital from a public company's balance sheet rather than a committed fund structure, investable assets are not reported as a separate pool. The parent company's total market capitalization and cash holdings are available through Shenzhen Stock Exchange filings.

Yuwell participates as a minority investor in Yunnan Baiyao, one of China's best-known traditional-medicine companies. New Huadu Industrial Group, the investment holding company of Chen Fashu, is also a strategic shareholder in Yunnan Baiyao alongside Yuwell, reflecting overlapping investment circles among influential Chinese corporate investors (per Caixin, 2019).